chronic kidney disease

54 all articles · 20 / page

Ask MedXY AI

Latest news

Tag

All articles

Deciphering Healthcare Costs in Type 2 Diabetes and Incident CKD: A Latent Class Trajectory Analysis in Hong Kong

A longitudinal study using Latent Class Analysis identifies four distinct phenotypes of T2D patients developing CKD, highlighting young-onset and middle-aged low-comorbidity groups as primary drivers of healthcare costs.

Section: Clinical UpdatesMar 28, 2026

Healthcare Economic Trajectories in Type 2 Diabetes and Incident CKD: Insights from a Latent Class Analysis in Hong Kong

This review analyzes a latent class trajectory study identifying four clinical phenotypes of T2D-related CKD, revealing that young-onset patients incur the highest longitudinal healthcare costs.

chronic kidney disease

Latest news

Deciphering Healthcare Costs in Type 2 Diabetes and Incident CKD: A Latent Class Trajectory Analysis in Hong Kong

Healthcare Economic Trajectories in Type 2 Diabetes and Incident CKD: Insights from a Latent Class Analysis in Hong Kong

Interaction Between SGLT2 Inhibition and Dietary Sodium: Insights from the CREDENCE Trial Post Hoc Analysis

SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes: A Comparative Effectiveness Review

Precision Diagnostics in Alzheimer’s Disease: Optimizing Plasma p-tau217 Cutoffs for Patients with Comorbidities

Renal Function and Metabolic Risk: Reduced eGFR Does Not Independently Increase DKA Risk in Type 1 Diabetes

Mechanistic Insights into APOL1-Mediated Hypertension: The STING-Endothelin 1 Axis as a Therapeutic Target

SGLT2 Inhibitors for All? Meta-Analysis Confirms Broad Clinical Benefits Regardless of Diabetes or Albuminuria Levels

SGLT2 Inhibitors Provide Robust Kidney Protection Across All Stages of CKD and Levels of Albuminuria: Evidence from the SMART-C Meta-Analysis

Beyond the Plate: Mediterranean Lifestyle as a Potent Shield Against Chronic Kidney Disease

Holistic Mediterranean Lifestyle Linked to 35 Percent Lower Risk of Incident Chronic Kidney Disease

Beyond Insulin: GLP-1 and SGLT2 Inhibitor Combination Therapy Targets Obesity and Kidney Disease in Type 1 Diabetes

GLP-1 Receptor Agonists Significantly Reduce MACE Risk Across the CKD Spectrum, Yet Prescription Rates Remain Suboptimal

Oral Semaglutide Slows eGFR Decline in Patients with Type 2 Diabetes and High Cardiovascular Risk: Insights from the SOUL Trial

Complete Revascularization Benefits Older MI Patients Regardless of Renal Function: Insights from the FIRE Trial

Finerenone Extends Cardiorenal Protection Across the Kidney Risk Spectrum in HFmrEF and HFpEF: Insights from FINEARTS-HF

Interleukin-6 Inhibition: A New Frontier in Reducing Residual Cardiovascular and Renal Risk

Protecting Your Kidneys and the Planet: The Impact of the Planetary Health Diet on Chronic Kidney Disease